Abstract
A retrospective study was conducted in a clinic specialized in treating individuals with developmental disabilities to examine the effectiveness and tolerability of quetiapine in children and adolescents with pervasive developmental disorders. Ten consecutive outpatients (age = 12.0 ± 5.1 years) treated with quetiapine (dose = 477 ± 212 mg, duration = 22.0 ± 10.1 weeks) were identified and six were judged to be responders based on impressions from chart review and Conners Parent Scale (CPS). Improvements were observed in the conduct, inattention, and hyperactivity subscales of the CPS. Adverse events were mild with sedation being the most common, and no patient required treatment termination. Quetiapine may be beneficial in children and adolescents with pervasive developmental disorders, however open-label and double-blind, placebo-controlled studies are warranted.
Similar content being viewed by others
References
A. M. Adityanee S. C. Schulz (2002) ArticleTitleClinical use of quetiapine in disease states other than schizophrenia Journal of Clinical Psychiatry 63 IssueIDSuppl. 13 32–38
L. A. Arvanitis B. G. Miller (1997) ArticleTitleMultiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo The Seroquel Trial 13 Study Group. Biological Psychiatry 42 233–246
S. R. David C. C. Taylor B. J. Kinon A. Breier (2000) ArticleTitleThe effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia Clinical Therapeutics 22 1085–1096
R. L. Findling (2002) ArticleTitleUse of quetiapine in children and adolescents Journal of Clinical Psychiatry 63 IssueIDSuppl. 13 27–31
C. H. Goyette C. K. Conners R. F Ulrich (1978) ArticleTitleNormative data on revised Conners Parent and Teacher Rating Scales Journal of Abnormal Child Psychology 6 221–236
Guy W., (1976). ECDEU Assessment Manual of Psychopharmacology. Rockville, MD: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs
D. L. Kleinberg J. M. Davis R. Coster Particlede B. Baelen ParticleVan M. Brecher (1999) ArticleTitleProlactin levels and adverse events in patients treated with risperidone Journal of Clinical Psychopharmacology 19 57–61
R. P. Malone M. Ernst K. A. Godfrey J. J. Locascio M. Campbell (1991) ArticleTitleRepeated episodes of neuroleptic-related dyskinesias in autistic children Psychopharmacology Bulletin 27 113–117
A. Martin K. Koenig L. Scahill J. Bregman (1999) ArticleTitleOpen-label quetiapine in the treatment of children and adolescents with autistic disorder Journal of Child Adolescent Psychopharmacology 9 99–107
B. J. McConville L. A. Arvanitis P. T. Thyrum C. Yeh L. A. Wilkinson R. O. Chaney et al. (2000) ArticleTitlePharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders Journal of Clinical Psychiatry 61 252–260
InstitutionalAuthorNameResearch Units on Pediatric Psychopharmacology Autism Network (2002) ArticleTitleRisperidone in children with autism and serious behavioral problems New England Journal of Medicine 347 314–321
B. J. Sadock V. A. Sadock H. I. Kaplan (2001) Kaplan & Sadock’s pocket handbook of clinical psychiatry (3rd ed.) Lippincott Williams & Wilkins Philadelphia
J. A. Shaw J. E. Lewis S. Pascal R. K. Sharma R. A. Rodriguez R. Guillen et al. (2001) ArticleTitleA study of quetiapine: Efficacy and tolerability in psychotic adolescents Journal of Child Adolescent Psychopharmacology 11 415–424
D. M. Taylor R. McAskill (2000) ArticleTitleAtypical antipsychotics and weight gain – a systematic review Acta Psychiatrica Scandinavica 101 416–432
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hardan, A.Y., Jou, R.J. & Handen, B.L. Retrospective Study of Quetiapine in Children and Adolescents with Pervasive Developmental Disorders. J Autism Dev Disord 35, 387–391 (2005). https://doi.org/10.1007/s10803-005-3306-1
Issue Date:
DOI: https://doi.org/10.1007/s10803-005-3306-1